Online inquiry

N-[1-(2,3-Dioleoyloxy)Propyl]-N,N,N-Trimethyl Ammonium Chloride (DOTAP)

Creative Biolabs has been a long-term expert in the field of mRNA therapeutics. To achieve efficient and safe delivery of mRNA, now we are proud to offer a series of reagents, especially N-[1-(2,3-Dioleoyloxy)Propyl]-N,N,N-Trimethyl Ammonium Chloride (DOTAP).

Introduction of N-[1-(2,3-Dioleoyloxy)Propyl]-N,N,N-Trimethyl Ammonium Chloride (DOTAP)

N-[1-(2,3-Dioleoyloxy)Propyl]-N,N,N-Trimethyl Ammonium Chloride (DOTAP) is a common quaternary ammonium compound. Different from other liposomal reagents, the DOTAP liposomal transfection reagent present highly efficient both in the absence and presence of serum. This reagent is suitable for the efficient transfer of negatively-charged molecules, including DNA, RNA, oligonucleotides, nucleotides, proteins, and ribonucleoprotein (RNP) complexes.

DOTAP-based SORT Nanoparticles

mRNA therapeutics present great potentials for the treatment of diseases with pathogenic mutations from multiple cell sources. The novel selective organ targeting (SORT) strategy is compatible with mRNA gene-editing technology and further provides the ability to target tissues.

As a well-known quaternary amino lipid, DOTAP has been used for the construction of selective organ targeting (SORT) nanoparticles. Studies showed that the DOTAP percentage is the main factor affecting the bio-distribution of cationic lipid nanoparticles. When the percentage of DOTAP lipid is increased from 5% to 100%, the expression of mRNA gradually shifts from the liver to the spleen, and then to the lungs.

DOTAP in mRNA Immunotherapies

In addition, the mRNA-lipoplexes composed of DOTAP/DOPE lipids gradually reduce their surface charge from positive to negative can protect antigen-encoding mRNA from extracellular ribonucleases. After systemic administration, this construct can deliver the mRNA into dendritic cells and induce an antigen-specific immune response. DOTAP-based nanostructures have been proved to induce the activation of TLRs and NLRP3 inflammasome pathways so that provide superior immunogenicity and therapeutic efficacy for mRNA immunotherapies.

As a pioneer and the undisputed global leader in mRNA therapeutics, we are pleased to use our extensive experience and advanced platform to offer the best service and the most qualified products to satisfy each demand from our customers. If you are interested in our products or services, please do not hesitate to contact us for more detailed information.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.